Glenmark Pharmaceuticals launches AKYNZEO I.V in India

23 Jan 2023 Evaluate

Glenmark Pharmaceuticals has launched a unique I.V. injection formulation, AKYNZEO I.V., in India for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.

AKYNZEO I.V. is a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute I.V. injection. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV. The drug is already being marketed in the EU, the US, and Australia.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2003.10 2.50 (0.12%)
19-Jan-2026 09:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1655.60
Dr. Reddys Lab 1174.85
Cipla 1386.00
Zydus Lifesciences 858.75
Lupin 2153.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×